You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯康生物科技集團(00690.HK)年內溢利飆升16.8%至8280萬港元 末期息0.277港仙
格隆匯 03-27 23:46

格隆匯3月27日丨聯康生物科技集團(00690.HK)公佈年度業績,截至2024年12月31日止年度,集團收益按年增長14.1%至約5.53億港元。年內溢利按年飆升16.8%至約8280萬港元,創歷史新高。該等業績再次印證集團作為領先生物製藥公司的穩固市場地位及其提供可持續高質量增長的能力。擬派末期股息每股股份0.277港仙。

博固泰®於2024年1月獲批,隨後於2024年3月上市,實現銷售額6290萬港元,超出最初預期。

於2024年12月,集團成功推出其自主研發的醫美產品肌顏態?。與重慶民濟醫療器械有限公司合作開發的重組膠原蛋白敷料獲得了二類醫療器械批准,強化了集團對創新皮膚修復解決方案的承諾。

於2024年1月,藥監局正式受理地誇磷索鈉滴眼液的上市申請,標誌集團眼科藥物研發管線的一個重要里程碑。

年內,集團已完成硫酸艾沙康唑膠囊的藥物研究及生物等效性預研究。正式的生物等效性試驗將於2025年啟動,以加速該藥物的上市進程。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account